Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combination of Nimotuzumab and Radiotherapy for Recurrent and Metastatic Uterine Cervical Squamous Carcinoma: a Single-arm, Open, Phase 2 Clinical Trial

NCT04664244 is registered in ClinicalTrials.gov with Lei Li as lead sponsor.

NCT NCT04664244
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04664244 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combination of Nimotuzumab and Radiotherapy for Recurrent and Metastatic Uterine Cervical Squamous Carcinoma: a Single-arm, Open, Phase 2 Clinical Trial
Lead sponsor
Lei Li
Phase
Phase 2
Overall status
Unknown status
Start date
December 19, 2020
Completion date
December 31, 2023
Enrollment
43 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

epidermal growth factor receptor, nimotuzumab, objective response rate, overall survival, progression-free survival, radiotherapy, recurrent cervical carcinoma